Articles On Alcidion Group (ASX:ALC)

Alcidion increased sales significantly in the first half Cogstate sounds warning on outlook Probiotic had a super half   Most biotech firms on the ASX are clinical stage companies, meaning they are still trying to prove that their drugs a...

A $1 million portfolio might seem like a far-off dream unless you start by investing an already large sum of money. Though, picking ASX shares with the potential for returns greater than 2,000% over the long term makes this dream much more...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

There have been countless quarterly updates released on Monday. Some have been received well by investors, others less so. Three that haven’t gone down particularly well with investors are summarised below. Here’s why these ASX All Ord...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Alcidion (ALC) has penned an extension to its agreement with Leidos Australia for the additional delivery of a management system to support healthcare services across the Australian Defence Force (ADF)The contract extension is expected to h...

Highlights The ASX 200 benchmark index closed in the green today (December 1), gaining 65.50 points or 0.90% to end at 7,349.70 points. Over the last five days, the index has gained 1.49%, but is down 1.27% for the last year to date....

Alcidion (ALC) signs a three-year agreement with the University Hospital Southampton NHS Foundation Trust (UHS) to implement its Miya Precision IT platformThe $2.8 million contract will see the company deliver a modern, modular electronic p...

Kazia’s positive results published in a Journal Cochlear’s proposed acquisition raised concerns with the ACCC Aldion signs multi-million dollar deal Kazia’s positive results get published Oncology biotech Kazia Therapeutics (ASX:KZA) ann...

According to Oxford Languages, ‘motley’ means “incongruously varied in appearance or character”. But in relation to our Foolish writers, it means they vary greatly with regard to age, risk tolerance, and stage of life as well as in...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

It’s been a rough year for investors of small-cap ASX shares. “All types of investing require nerve and courage. But perhaps none more so than small-cap stocks,” said Ophir analysts in a memo to investors this month. “When an economic down...

The Dubber Corp Ltd (ASX: DUB) share price will emerge from the ASX suspension on Monday. I’m guessing the Dubber share price will be punished. For context, I wrote last week why Dubber shares were suspended. I have no dog in this fight — f...

Claude Walker is the founder of A Rich Life and a small-cap investing expert. Claude joins Owen Rask on The Australian Investors Podcast to help us understand where we might be in the market cycle, and the duo identifies two of their favour...

The Australian Investors Podcast welcomes back Claude Walker, founder of A Rich Life, to talk about 5 companies that caught his eye during ASX Reporting Season, including Objective Corporation Ltd (ASX: OCL), PWR Holdings (ASX: PWH) and mor...

Dubber Corp Ltd (ASX: DUB), Alcidion Group Ltd (ASX: ALC), Fortescue Metals Group Ltd (ASX: FMG) and Wesfarmers Ltd (ASX: WES) feature on this week’s Australian Investors Podcast. Drew Meredith, CFP and Owen Rask are back on The Australian...

This week, we bid farewell to winter… and another tumultuous ASX earnings season. So now, looking ahead to the brighter days of spring, hopefully the stock market can also deliver some healthy new growth. Armed with a barrow full of inf...

The All Ordinaries Index (ASX: XAO) is in the green so far today. At the time of writing, it’s 0.52% higher at 7,231 points. Earnings season has been a busy one with plenty of mixed results. Here are three ASX All Ordinaries standouts that...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. At the time of writing, the benchmark index is up a fraction to 6,810.2 points. Four ASX shares that are climbing more than most tod...

The Alcidion Group Ltd (ASX: ALC) share price has been a strong performer on Wednesday. In afternoon trade, the healthcare technology company’s shares are up over 18% to 16 cents. This follows the release of Alcidion’s unaudited fourth...

Digital healthcare company Alcidion (ALC) achieves record quarterly cash receipts of $14 million for the June quarter Total cash receipts for FY22 came to $41.4 million, a 29 per cent increase on the prior year, resulting in positive opera...

Ask A Fund Manager The Motley Fool chats with the best in the industry so that you can get an insight into how the professionals think. In this edition, Cyan Investment Management portfolio manager Dean Fergie nominates a bargain ASX share...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Fears of rising interest rates have really taken their toll on growth and small-cap ASX shares. That’s because smaller, rapidly expanding businesses are typically the ones who have taken on debt to fuel their growth. And when a company bor...

This year has been a rough ride for most ASX shares, but small-cap companies have suffered more than their larger cousins. The Cyan C3G Fund, which specialises in small-cap stocks, has felt the pain as much as any retail investor. Portfoli...

Dean Fergie, is the co-founder of Melbourne-based Cyan Investment, where his 25 years in funds management across all major asset classes is poured into one single fund. Dean has absolutely no intention of being all things to all people. “We...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

In this episode of The Australian Investors Podcast, Owen Rask is joined by 7Investing’s Dr Anirban Mahanti to talk markets, the economy, how to value tech stocks and more. Stocks mentioned in the podcast include: Target Corporation (NYSE...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?...

If you’re wanting to invest in the small side of the Australian share market, then the three small caps listed below could be worth a closer look. Here’s why these small cap ASX shares could be worth adding to your watchlist: Adore Beauty...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Highlights The benchmark index ASX200 was down 0.817% at 7258.200 points at 3:22 PM AEST on Wednesday (27 April 2022). The S&P/ASX 200 Health Care Index (ASX:XHJ) was 1.380% lower at 40598.200 points during the intraday trading ses...

Digital healthcare company Alcidion Group (ALC) says the March quarter was a “very strong” period for the company Alcidion earned $12.5 million in new sales which contributed to nearly $43 million in year-to-date sales At the end of the th...

Alcidion (ASX:ALC) signs an agreement with Northern Territory Health (NT Health) that will see NT Health upgrade from an earlier version of Miya to Alcidion’s current Miya Precision platform NT Health will deploy the latest Miya Precision...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Cann will market its CBD capsules in Australia 4DMedical’s XV LVAS software is being trialed in a hospital in California Polynovo’s record March quarter Cann to market CBD capsules in Australia Cannabis company Cann Group (ASX:CAN) has en...

Digital medical information specialist Alcidion (ALC) signs a five-year agreement with East Lancashire Hospitals NHS Trust in the UK to implement the company’s Miya Precision, an upgrade to the existing ExtraMed patient flow solution The c...

Wall Streeet tumbled overnight on US Fed comments  Fed Governor Lael Brainard said the Fed will start reducing the Fed’s balance sheet in May Bond market also sold off ASX to slide as Wall Street tumbles Local shares are poised to fall to...

Alcidion Group (ALC) signs contract renewal agreements with existing customers Moorfields Eye Hospital and Liverpool Heart and Chest Hospital for the use of its Silverlink Patient Care System (PCS) solution Both hospitals are committing to...

Alcidion (ALC) signs a five-year agreement with Dartford and Gravesham NHS Trust to implement the company’s new Miya Emergency module The two software products are expected to alleviate pressure while focusing priorities for emergency dep...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

Alcidion (ALC) strikes a $1.35 million deal to supply its Miya Flow technology to Herefordshire and Worcestershire Health and Care NHS Trust for five years The NHS trust will deploy the tech across six community hospitals to streamline pat...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Cyan Investm...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Alcidion Group (ALC) signs a five-year agreement with the NHS Tayside with the NHS Tayside health board in Scotland to deploy its Miya Observations and Assessments solution The company says NHS Tayside is the third health board in Scotland...